Trial Profile

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Fludarabine (Primary) ; Hydrocortisone (Primary) ; Methotrexate (Primary) ; Tagraxofusp (Primary) ; Vincristine (Primary)
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition
14 Nov 2022 Planned End Date changed from 1 Nov 2027 to 11 Nov 2027.
14 Nov 2022 Planned primary completion date changed from 1 Nov 2025 to 11 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com